lovastatin | 83213-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: lovastatin
• 英文别名: 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2 H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate；Mevacor；[8-[2-(4-hydroxy-6-oxooxan-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2-methylbutanoate
• CAS: 83213-71-2
• 化学式: C₂₄H₃₆O₅
• 分子量: 404.547
• InChiKey: PCZOHLXUXFIOCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

ADMET

毒理性

• 在妊娠和哺乳期间的影响

母乳喂养期间使用概述：目前没有关于在母乳喂养期间使用洛伐他汀的相关已发表信息。由于担心会干扰婴儿的脂质代谢，共识认为在母乳喂养期间不应使用洛伐他汀。然而，也有人认为，对于家族性高胆固醇血症的纯合子儿童，从1岁开始就使用他汀类药物，他汀类药物的口服生物利用度较低，对哺乳婴儿的风险较低，尤其是瑞舒伐他汀和阿托伐他汀。[1]在更多数据可用之前，可能更倾向于使用其他药物，特别是在哺乳新生儿或早产儿时。 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发表信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发表信息。

◉ Summary of Use during Lactation:No relevant published information exists on the use of lovastatin during breastfeeding. Because of a concern with disruption of infant lipid metabolism, the consensus is that lovastatin should not be used during breastfeeding. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin.[1] Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为反应物：
  描述：

  lovastatin 生成 7-[2,6-Dimethyl-8-(2-methyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
  参考文献：
  名称：

  ALBERS-SCHONBERG, G.

  摘要：

  DOI：

文献信息

• COMPOUND, AND SEPARATION METHOD, SYNTHESIS METHOD AND USE THEREOF
  申请人：BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD.

  公开号：US20180022688A1

  公开（公告）日：2018-01-25

  The invention relates to new compounds as well as a separation method, a synthetic method and use thereof. It is demonstrated by an assay on activity that the compound has an activity of inhibiting an HMG-CoA reductase. In addition, the invention also relates to a derivative of the compound.

  该发明涉及新化合物，以及分离方法、合成方法和应用。通过活性测定表明，该化合物具有抑制HMG-CoA还原酶活性的作用。此外，该发明还涉及该化合物的衍生物。
• Process for preparing simvastatin and intermediates thereof
  申请人：Korodi Ferenc

  公开号：US20070129437A1

  公开（公告）日：2007-06-07

  Novel processes for the preparation of simvastatin and intermediates of such processes. Preferred embodiments include the preparation of lovastatin amides, protected lovastatin amide derivatives, simvastatin dihydroxy acid amide derivatives, alkali salts, simvastatin dihydroxy acids, simvastatin ammonium salts, and simvastatin.

  制备辛伐他汀和该过程的中间体的新型工艺。首选实施例包括洛伐他汀酰胺、保护洛伐他汀酰胺衍生物、辛伐他汀二羟基酸酰胺衍生物、碱盐、辛伐他汀二羟基酸、辛伐他汀铵盐和辛伐他汀的制备。
• [EN] ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER<br/>[FR] NANOPARTICULES ANTIOXYDANTES, NEUROPROTECTRICES ET ANTINÉOPLASIQUES COMPRENANT UN AGENT THÉRAPEUTIQUE SUR UN ESPACEUR AMPHIPHILE OU UN POLYMÈRE AMPHIPHILE
  申请人：CEDARS SINAI MEDICAL CENTER

  公开号：WO2013016696A1

  公开（公告）日：2013-01-31

  This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs.

  本发明涉及抗氧化剂、神经保护剂和抗肿瘤纳米粒子，其包括具有治疗剂的两性亲脂间隔物或两性亲脂聚合物。还提供了合成伯氨替芬的抗氧化剂衍生物和伯氨替芬类似物、NSAIDs和他汀类药物的抗氧化剂衍生物的方法，以及通过自发乳化或纳米沉淀制备这些抗氧化、神经保护和抗肿瘤纳米粒子，其包括具有治疗剂的两性亲脂间隔物或两性亲脂聚合物，并且它们在治疗癌症疾病中的应用。本发明的另一个方面是利用这些神经保护和抗肿瘤纳米粒子制备其他药物和/或药物的输送装置。
• HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND
  申请人：Burgos Muñoz Javier Santos

  公开号：US20130197073A1

  公开（公告）日：2013-08-01

  The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for use in the prevention of: neurodegenerative diseases, cognitive impairment, diseases associated with undesired oxidation, age-associated pathological processes and progeria, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipidemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.

  本发明描述了式(I)的化合物，其羟基酸形式，所述羟基酸的药学上可接受的盐，以及所述化合物及其羟基酸形式的药学上可接受的前药和溶剂化物，特别是所述化合物、其羟基酸形式、盐等用于预防：神经退行性疾病、认知障碍、与不良氧化相关的疾病、年龄相关的病理过程和早衰、心血管疾病，如动脉粥样硬化、心房颤动、血脂异常、高胆固醇血症、高脂血症和高甘油三酯血症、炎症或炎症过程，或癫痫、癫痫发作和惊厥。
• PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS
  申请人：Acemoglu Murat

  公开号：US20080182873A1

  公开（公告）日：2008-07-31

  The invention relates to a process for the manufacture of a compound of formula or a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the element represents —CH 2 —CH 2 — or —CH═CH— and R represents a cyclic residue.

  本发明涉及一种制备化合物的方法，该化合物的化学式为或其盐，特别是与碱形成的药学上可接受的盐或其内酯，其中元素代表—CH2—CH2—或—CH═CH—，R代表一个环状残基。

表征谱图